Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05143970
Title A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (CHANCES)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Institut Paoli-Calmettes
Age Groups: adult | senior
Covered Countries FRA

No variant requirements are available.